238 Users Online
Single-Cell Analysis Market Segmented by Instruments (Manual Instruments - Microscopes and Hemocytometers), and (Automated Instruments - Flow Cytometers, Next Generation Sequencing)
The global single-cell analysis market was valued at US$ 3.30 Billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 20% from 2022 to 2032.
The rising prevalence of cancer worldwide and rapid development of technologies have cascaded huge investments from life sciences companies and government funding initiatives for research activities. The research and development (R&D) in the field of medical and clinical diagnostics, the availability of advanced technologies such as sequencing, and the increasing adoption of single-cell analysis devices to understand the central dogma of molecular biology are some of the factors that are contributing to the growth of the market.
Single-cell analysis Market Size (2022)
US$ 3.96 Billion
Projected Market Value (2032)
US$ 24.52 Billion
Global Market Growth Rate (2022-2032)
The COVID-19 pandemic positively impacted the market for single-cell analysis (SCA). The pandemic has triggered the widespread adoption of SCA methods in virology research. In 2021, the single cell isolation and library preparation segment accounted for the largest revenue share of over 35.0%.
The vast range of applications for SCA has subsequently increased the demand for cell isolation and library preparation products such as kits and reagents. In addition, a substantial number of industry players are offering a range of products for single-cell isolation, to name a few, FACS and MACS for heterogeneous cell suspensions, microdissection of fixed tissue samples, flow cytometry, and microfluidics, in this segment, in turn, augmenting the revenue growth.
In the years to come, the downstream analysis segment is gaining traction owing to the technological advancements over the past few years. Technologies such as the emergence of next-generation sequencing for analyzing cellular expressions, mass spectrometry, and FISH (Fluorescence in situ hybridization) have proven to be important tools for SCA. Also, the market is witnessing the increasing automation of machines and artificial intelligence for data analysis.
Several software and computational methods have been developed and are being employed due to their benefits such as scalability, flexibility, and high success rates. For example, as of 2021, there were over 1000 single-cell RNA analysis tools. Thus, this high growth of database tools reflects the interest and availability of SCA technologies, which, in turn, will spur industry growth in the near future.
Rising Inclination towards advancement in human health anticipated to drive the global market
To understand the immune response and the long-term effects of infections, researchers are utilizing the specimens from COVID-19 biobanks for performing analysis to comprehend the profiles of infected patients. For instance, in March 2021, the researchers from The NHLBI LungMap Consortium and The Human Cell Atlas Lung Biological Network performed a single-cell meta-analysis in 1,320,896 cells from 228 humans. This study was aimed at understanding the entry genes of SARS-CoV-2 across demographics.
The demand for SCA is growing in omics research activities, including genomics, proteomics, transcriptomics, and metabolomics. The study of single-cell omics helps in the analysis of huge data sets and understanding the genetic basis. It is the key to mastering the advancement in human health via disease diagnosis and drug discovery. The technological development has resulted in high throughput assays, efficient cell sorting and tagging, sequencing, microfluidics, single-cell amplification, and advanced software tools. The availability of these products and vast application areas are organically increasing the revenue of this market.
Growing Demand for Analytical Tools for Innovative Research to Propel Market Growth
The growing demand for analytical tools for innovative research and subsequent funding has led to the introduction of high-throughput equipment within the market. Multiple innovations have led this equipment to involve features such as automation, high sensitivity, and accuracy, which ultimately help in analyzing scarce samples.
For example, in March 2022, Deepcell Inc., a U.S.-based company, received funding of USD 73 million to accelerate its AI-powered single cell analysis platform and move towards commercialization.
Thus, key players are significantly investing in developing solutions leading to a lucrative opportunity for revenue generation in the upcoming years. However, the market penetration will face hindrance due to the high cost of these instruments and consumables. The continuous maintenance costs and other expenses related to these products will create constraints for several clinical and research applications with budget limitations.
High Cost of Research Restraining the Market Growth
The high cost of research of single-cell biology to maintain high-quality standards (the use of high-grade, expensive products) and comply with the guidelines set by regulatory authorities is likely to restrain the market growth. Research and academic laboratories find it difficult to afford such expensive instruments due to budget constraints. In addition, the maintenance costs and several other indirect expenses result in an increased overall cost.
Rising Development of Healthcare Infrastructure Driving Market for Single-Cell Analysis
North America dominated the global market with a revenue share of over 35.0% in 2021. This can be attributed to factors such as multiple government funding programs, rising awareness regarding personal healthcare and related expenditure, faster adoption of novel analytical tools and techniques, and the availability of trained personnel.
Asia Pacific is expected to exhibit the fastest CAGR over the forecast period. In the past years, the growing medical industry, rapidly developing healthcare systems, and increasing geriatric population have resulted in fueling the demand for cutting-edge diagnostic tools in the emerging economies of Asia Pacific. The focused efforts and outsourcing in this region have led to significant growth.
Why are Suppliers of single-cell analysis investing in the U.S.?
Supportive Government Initiatives & High Spending on Healthcare R&D
The United States is known for its developed healthcare infrastructure and extensive research activity, which makes it a favorable market for single-cell analysis. The presence of modern healthcare infrastructure and the presence of leading market players also make the U.S. a highly rewarding market for single-cell analysis suppliers and manufacturers. Increasing support from the government of the U.S. is another factor that will uplift single-cell analysis market potential over the coming years.
Additionally, the high incidence of chronic diseases such as cancers in the region is driving the market growth. Also, the existence of major players in the region and new product launches is expected to boost the single-cell analysis market.
For instance, in March 2021, The United States Food and Drug Administration approved Abecma (idecabtagene vicleucel), to treat adult patients with multiple myeloma who have not responded to, or whose disease has returned after, at least four prior lines of therapy. Abecma is the first cell-based gene therapy approved by the FDA for the treatment of multiple myeloma. Thus, owing to the above-mentioned factors, the single-cell analysis market is expected to witness significant growth over the forecast period in North America.
The U.S. is a major contributor to the industry growth in North America. For example, the U.S. NIH (National Institutes of Health) through its Common Fund Programs is supporting metabolomics research. Formerly, the NIH had also supported the single cell analysis program (SCAP) through the same funds. Extraordinary healthcare infrastructure, demand for personalized medicines, and the presence of key market players are some of the key factors fueling regional growth.
How Will the Chinese Single-Cell Analysis Market Evolve?
Increasing healthcare expenditure to boost the Regional Market Growth
Focus on healthcare in China is increasing and this trend was particularly boosted by the outbreak of coronavirus in 2020, which is expected to primarily drive single-cell analysis market potential in the country through 2032. Increasing healthcare expenditure, and favorable government policies to boost healthcare infrastructure development are other factors that positively impact single-cell analysis market growth in China. Furthermore, numerous pharmaceutical and biotechnology companies are major end users in the region.
Which Application Accounts for Highest Demand for Single-Cell Analysis?
Cancer to account for a high Market Share
The cancer segment captured the largest revenue share of over 30.0% in 2021. Single-cell analysis has proved to be effective for the diagnosis of cancer cells. The genetic variation via cell proliferation conditions, mutation rates, and cell types can be easily identified using these techniques.
As per the American Cancer Society, cancer is the second most common cause of death in the U.S. after heart disease. According to cancer statistics, in 2022, 1.9 million new cancer cases are expected to occur in the U.S. Thus, the increasing prevalence of cancer and the never-ceasing studies and developments in this field are anticipated to positively impact the industry growth.
The existence of a significant number of research activities for evaluating single-cell genomics and proteomics has led to the increasing implementation of SCA methods in therapeutics and diagnostics applications. Moreover, increasing demand for stem cell therapies for regenerative and personalized medicines is bolstering this market space. Therapies like regeneration of hair, transplants of tissue, and organ and bone marrow are boosting the usage rates of single-cell analysis techniques.
By Product Type, which Segment is Driving Market Growth?
Consumables Segment type is expected to grow at a significant rate
The consumables segment held the largest revenue share of over 50.0% in 2021 and is projected to exhibit a significant CAGR from 2022 to 2030 owing to the high usability of isolation products, large-scale adoption of cell sorting beads, frequent purchase of buffers and reagents, and growing demand for assay kits. An increase in the prevalence of target diseases and the constant need for consumables required for the assays during scientific activities are propelling the segment growth.
Moreover, the extensive use of consumables such as reagents throughout SCA assays creates a continuous high demand for these products. These reagents are available in different forms including probes, cellular markers, multicolor cocktails, and even phenotyping agents. The robust activities of scientific entities have resulted in the massive adoption and purchase of reagents, thus leading to revenue generation in the global market.
The installation of new instruments, replacement of old instruments, and services related to instruments led to revenue generation for the instruments segment. Owing to the high-end features and the technically advanced analytical options, the automated instruments are anticipated to witness significant growth during the forecast period.
Which End User Shows Higher Implementation in Single-Cell Analysis Market?
Demand from Academic and Research Laboratories to Gain Traction
The academic and research laboratories accounted for the largest revenue share of 70% in 2021 due to the wide use of single-cell analysis technology in research settings. The considerable number of ongoing scientific projects at various universities employing SCA techniques has driven its adoption in 2021. The introduction of spatial genomics accelerates the single-cell analysis in research activities, which is another key factor driving the segment.
Furthermore, developing new tools to tackle the research limitation is driving the market, for example, researchers at Stony Brook University, New York developed a new biomedical research tool, single-cell cyclic multiplex in situ tagging (CycMIST) technology in June 2022. This technology enables scientists to assess functional proteins in a single cell and contribute to the diagnostic and discovery fields.
Top companies in the single-cell analysis market are focusing on advancing their research and fast-tracking the development of new single-cell analysis to launch new products and gain a competitive advantage over other market players.
Major players are channelling efforts toward expanding their production capacities to strengthen their market share and cater to the growing demand for fatty amides. Market expansion is anticipated to be aided by the growing number of partnerships and collaborations among key players that are looking to increase their presence in the market.
Historical Data Available For
US$ Bn for Value
Key Countries Covered
By Market Segments
Key Companies Profiled
Available Upon Request
By Application Type
By End User
The global single-cell analysis market accounts for a revenue of US$ 3.96 Billion in 2022.
The global market for single-cell analysis is expected to reach US$ 24.52 billion by 2032.
Demand for single-cell analysis from 2022 to 2032 is projected to expand at a stellar CAGR of 20%.
By 2032, the consumables segment is projected to hold a maximum share of 50% of the market.
Key suppliers of single-cell analysis are Thermo Fisher Scientific Inc.; QIAGEN NV; Bio-Rad Laboratories Inc.; Illumina Inc.; Merck KGaA; Becton, Dickinson & Company; Fluidigm Corporation; 10x Genomics, Inc.; BGI; Novogene Corporation.